Aromatase inhibitors: development and current perspectives
By: Sayyad, Nusrat B
.
Contributor(s): Sabale, Prafulla M.
Publisher: Karnataka Association of Pharmaceutical Teachers of India (APTI) 2022Edition: Vol.56(2), Apr-June.Description: 311-320p.Subject(s): PHARMACEUTICSOnline resources: Click here
In:
Indian journal of pharmaceutical education and researchSummary: Aim: Breast cancer is one of the most common cancers among women, consistently
elevated estrogen level in the blood associated with persistently in breast cancer found in
many studies. The mechanisms of carcinogenesis whereby cancer is associated involved
in the conversion of androgen to estrogen in the presence of enzyme aromatase. Materials
and Methods: Aromatase is a (CYP19), a cytochrome P450, which is the enzyme that
synthesizes estrogen. Aromatase which is expressed in higher concentration in breast
play a pivotal role in the origin and progression of breast cancer.
In situ inhibition of
aromatase enzyme accomplished by the prevention of aromatase expression in breast
cancer. Results: The success of aromatase inhibition could result in the suppression and
progression of breast cancer. One of the ways to reduce the incidence of breast cancer by
inhibiting estrogen biosynthesis in breast tissue. Aromatase inhibitor therapy is considered
for second-line treatment in patients who fail anti-estrogen therapy. Conclusion: Several
potent and selective aromatase inhibitors have been developed and used to treat breast
cancer. Some of them have passed clinical trial phase II. Development in the field has
encouraged us to review work on the Aromatase inhibitor.
| Item type | Current location | Call number | Status | Date due | Barcode | Item holds |
|---|---|---|---|---|---|---|
Articles Abstract Database
|
School of Pharmacy Archieval Section | Not for loan | 2022-1415 |
Aim: Breast cancer is one of the most common cancers among women, consistently
elevated estrogen level in the blood associated with persistently in breast cancer found in
many studies. The mechanisms of carcinogenesis whereby cancer is associated involved
in the conversion of androgen to estrogen in the presence of enzyme aromatase. Materials
and Methods: Aromatase is a (CYP19), a cytochrome P450, which is the enzyme that
synthesizes estrogen. Aromatase which is expressed in higher concentration in breast
play a pivotal role in the origin and progression of breast cancer.
In situ inhibition of
aromatase enzyme accomplished by the prevention of aromatase expression in breast
cancer. Results: The success of aromatase inhibition could result in the suppression and
progression of breast cancer. One of the ways to reduce the incidence of breast cancer by
inhibiting estrogen biosynthesis in breast tissue. Aromatase inhibitor therapy is considered
for second-line treatment in patients who fail anti-estrogen therapy. Conclusion: Several
potent and selective aromatase inhibitors have been developed and used to treat breast
cancer. Some of them have passed clinical trial phase II. Development in the field has
encouraged us to review work on the Aromatase inhibitor.
Click on an image to view it in the image viewer
There are no comments for this item.